公开(公告)号：US20180273631A1

公开(公告)日：2018-09-27

申请号：US15934334

申请日：2018-03-23

申请人： UNIVERSITY OF SOUTHAMPTON

发明人： Martin John GLENNIE ,  Alison Louise TUTT ,  Aymen AL-SHAMKHANI

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/75 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466

摘要： Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

公开(公告)号：US20200247898A1

公开(公告)日：2020-08-06

申请号：US16782282

申请日：2020-02-05

申请人： UNIVERSITY OF SOUTHAMPTON

发明人： Martin John GLENNIE ,  Alison Louise TUTT ,  Aymen AL-SHARNKHANI

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395

摘要： Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

公开(公告)号：US20160215056A1

公开(公告)日：2016-07-28

申请号：US14974793

申请日：2015-12-18

申请人： UNIVERSITY OF SOUTHAMPTON

发明人： Martin John GLENNIE ,  Alison Louise TUTT ,  Aymen AL-SHARNKHANI

IPC分类号： C07K16/28

CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/75 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466

摘要： Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

摘要翻译： 提供了用于治疗其中抗原特异性T细胞免疫应答是治疗期望的条件的体内T细胞增殖和扩增的方法，例如癌症，感染，炎症，过敏和自身免疫以及用于增强疫苗的功效。 这些方法包括单独给予至少一种CD27激动剂，优选激动性CD27抗体，或与另一部分如免疫兴奋剂或免疫调节剂如抗-CD40，OX-40，4-1BB或CTLA- 4抗体或消耗调节细胞或细胞因子的药剂。 这些单一和组合疗法还可以任选地包括施用期望的抗原，例如肿瘤抗原，变应原，自身抗原或对感染性或病原体特异性的抗原，其中希望引起T细胞应答（通常是CD8 +） 。